IOL Chemicals Expands Ibuprofen Capacity by 6,000 MTPA, Enters CDMO Business
IOL Chemicals is expanding its Ibuprofen capacity by 6,000 MTPA to 18,000 MTPA with a ₹350 Crore investment. It is also entering the CDMO business for pharmaceutical formulations with a ₹110 Crore facility, expected to commercialize in Q3 FY2027. Additionally, a ₹35 Crore specialty chemicals facility under a tolling arrangement will be commercialized in Q3 FY2027.
The expansion of a key product's capacity and entry into new, high-potential business segments like CDMO and specialty chemicals are likely to have a substantial impact on the company's future revenue and market position.
The announcement details significant capacity expansions and diversification into new business areas (CDMO and specialty chemicals), which are positive developments for the company's growth strategy.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has announced significant business and capacity expansion initiatives. The company is expanding its Ibuprofen manufacturing capacity by 6,000 MT per annum, increasing its total capacity to 18,000 MT per annum. This expansion, estimated to cost ₹350 Crore, will be funded through internal accruals and is expected to be commercialized by December 2027.
In a strategic diversification, IOLCP has also established a new pharmaceutical formulation manufacturing facility for Contract Development and Manufacturing Organisation (CDMO) services. This facility, with a capacity of approximately 1,500 million tablets per annum, represents an investment of ₹110 Crore, funded by internal accruals. The CDMO facility has received GMP Certificate from Hungary and is expected to be commercialized in Q3 FY 2027, catering to European customers.
Furthermore, IOLCP is setting up a dedicated specialty chemicals manufacturing facility under a long-term tolling arrangement for a leading global chemical company. This project involves a capital expenditure of approximately ₹35 Crore, funded by internal accruals, and is also expected to be commercialized in Q3 FY 2027.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.